Health and Fitness Health and Fitness
Tue, March 12, 2013
[ Tue, Mar 12th 2013 ] - Market Wire
USANA's Timothy quot;;Desert Stormquot;; Bradley To Defend WBO Title
[ Tue, Mar 12th 2013 ] - Market Wire
Cytomedix to Host Fourth Quarter and Fiscal Year .. esults Conference Call on Tuesday, March 19, 2013
[ Tue, Mar 12th 2013 ] - Market Wire
Echo Therapeutics Granted U.S. Patent for Prelude SkinPrep System
[ Tue, Mar 12th 2013 ] - Market Wire
Frost amp;; Sullivan Applauds Galena Bioph .. its Breakthrough Breast Cancer Vaccine, NeuVaxa"
[ Tue, Mar 12th 2013 ] - Market Wire
Simcere Pharmaceutical Group Announces its Special Committee's Engagement of Legal Counsel
[ Tue, Mar 12th 2013 ] - Market Wire
Boston Therapeutics Appoints Peter Sheehan, M.D. as Medical Director
[ Tue, Mar 12th 2013 ] - Market Wire
EnteroMedics to Present at 25th Annual Roth Capital Partners Conference
[ Tue, Mar 12th 2013 ] - Market Wire
Government Security News Features Implant Sciences
Mon, March 11, 2013
[ Mon, Mar 11th 2013 ] - Market Wire
Patient Home Monitoring Announces Expansion into .. ith a Letter of Intent to Acquire LM Pharmacy Sol
[ Mon, Mar 11th 2013 ] - Market Wire
Lakeland Industries, Inc. Reports Material Developments
[ Mon, Mar 11th 2013 ] - Market Wire
Cleveland Clinic and Community Health Systems Form Strategic Alliance
[ Mon, Mar 11th 2013 ] - Market Wire
Venaxis to Present at 25th Annual ROTH Conference
[ Mon, Mar 11th 2013 ] - Market Wire
Thoratec Presentation At Barclays Global Healthcare Conference To Be Webcast
[ Mon, Mar 11th 2013 ] - Market Wire
Avanir Pharmaceuticals Announces Appointment of Corinne Nevinny to Board of Directors
[ Mon, Mar 11th 2013 ] - Market Wire
Abattis Terminates $600,000 Private Placement
[ Mon, Mar 11th 2013 ] - Market Wire
Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results
[ Mon, Mar 11th 2013 ] - Market Wire
Emerging Growth Equities, Ltd. Initiates Coverage .. . (SRPT) With a BUY Rating and $38.00 Price Targe
[ Mon, Mar 11th 2013 ] - Market Wire
Hill-Rom Elects William H. Kucheman to its Board of Directors
[ Mon, Mar 11th 2013 ] - Market Wire
Survival of SAPIEN High-Risk Patients Equivalent to Surgery at Three Years
[ Mon, Mar 11th 2013 ] - Market Wire
SurgiCount Medical Announces The Appointment Of M .. hael Roux As Vice President of Product Management
[ Mon, Mar 11th 2013 ] - Market Wire
VistaGen Therapeutics to Present CardioSafe 3D(TM .. ts at Society of Toxicology's 52nd Annual Meeting
[ Mon, Mar 11th 2013 ] - Market Wire
New Data Reinforce Strong Long-Term Clinical Perf .. Abbott's Absorba" Bioresorbable Vascular Scaffold
[ Mon, Mar 11th 2013 ] - Market Wire
GeoVax Labs Reports 2012 Financial Results and Progress
[ Mon, Mar 11th 2013 ] - Market Wire
Sirona Biochem Signs Material Transfer Agreement with VitamFero
[ Mon, Mar 11th 2013 ] - Market Wire
First Center in Hong Kong Treats Patients with CyberKnife and TomoTherapy Systems
[ Mon, Mar 11th 2013 ] - Market Wire
Outlook for Diagnostic Substances Industry
[ Mon, Mar 11th 2013 ] - Market Wire
Insmed to Host Fourth Quarter and Full Year 2012 .. Results Conference Call on Monday, March 18, 2013
[ Mon, Mar 11th 2013 ] - Market Wire
Suit Against Micro Imaging Technology Dismissed by Texas Court
[ Mon, Mar 11th 2013 ] - Market Wire
Simcere Pharmaceutical Group Announces Receipt of quot;;Going Privatequot;; Proposal
[ Mon, Mar 11th 2013 ] - Market Wire
Horizon Pharma to Present at the 25th Annual ROTH Conference

Horizon Pharma to Present at the 25th Annual ROTH Conference


Published on 2013-03-11 04:45:46 - Market Wire
  Print publication without navigation


March 11, 2013 07:30 ET

Horizon Pharma to Present at the 25th Annual ROTH Conference

DEERFIELD, IL--(Marketwire - Mar 11, 2013) - Horizon Pharma, Inc. (NASDAQ: [ HZNP ]), today announced that Timothy P. Walbert, chairman, president and chief executive officer will present at the 25th Annual ROTH Conference on Monday, March 18th at 8:30a.m. Pacific Time in Laguna Nigel, CA. Mr. Walbert will provide an overview of the Company and its corporate activities.

The presentation will be webcast live and may be accessed by visiting Horizon's website at [ http://ir.horizon-pharma.com ]. A replay of the webcast will be available for 10 business days.

About Horizon Pharma
Horizon Pharma, Inc. is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS/LODOTRA, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company's strategy is to develop, acquire, in-license and/or co-promote additional innovative medicines where it can execute a targeted commercial approach in specific therapeutic areas while taking advantage of its commercial strengths and the infrastructure the Company has put in place. For more information, please visit [ www.horizonpharma.com ].


Contributing Sources